TP3: Inhibition of the interaction of the FcRn with IgG autoantibodies

Autoimmune diseases are of growing clinical relevance and treatment is long and difficult. High doses of intravenous IgG (IVIG) are used in therapy. One mechanism of action discussed for IVIG is the blockade of the FcRn receptor due to the high amounts of IgG. Normally, IgG’s are the proteins with the longest serum half-life which is mediated by binding to the FcRn. The project aims at the inhibition of the IgG FcRn interaction to promote the break-down of autoantibodies.

Anna Tomhardt received her Dr. rer. nat. degree in 07/2015.